9-130494983-C-T
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PM1PM2PM5PP3_StrongPP5_Very_Strong
The NM_054012.4(ASS1):c.1087C>T(p.Arg363Trp) variant causes a missense change. The variant allele was found at a frequency of 0.0000341 in 1,613,130 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R363L) has been classified as Likely pathogenic.
Frequency
Consequence
NM_054012.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ASS1 | NM_054012.4 | c.1087C>T | p.Arg363Trp | missense_variant | 13/15 | ENST00000352480.10 | NP_446464.1 | |
ASS1 | NM_000050.4 | c.1087C>T | p.Arg363Trp | missense_variant | 14/16 | NP_000041.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ASS1 | ENST00000352480.10 | c.1087C>T | p.Arg363Trp | missense_variant | 13/15 | 1 | NM_054012.4 | ENSP00000253004.6 | ||
ASS1 | ENST00000372393.7 | c.1087C>T | p.Arg363Trp | missense_variant | 14/16 | 5 | ENSP00000361469.2 | |||
ASS1 | ENST00000372394.5 | c.1087C>T | p.Arg363Trp | missense_variant | 14/16 | 2 | ENSP00000361471.1 | |||
ASS1 | ENST00000372386.6 | n.358C>T | non_coding_transcript_exon_variant | 4/6 | 3 |
Frequencies
GnomAD3 genomes AF: 0.0000394 AC: 6AN: 152136Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000320 AC: 8AN: 250206Hom.: 0 AF XY: 0.0000222 AC XY: 3AN XY: 135400
GnomAD4 exome AF: 0.0000335 AC: 49AN: 1460994Hom.: 0 Cov.: 31 AF XY: 0.0000275 AC XY: 20AN XY: 726828
GnomAD4 genome AF: 0.0000394 AC: 6AN: 152136Hom.: 0 Cov.: 32 AF XY: 0.0000807 AC XY: 6AN XY: 74330
ClinVar
Submissions by phenotype
Citrullinemia type I Pathogenic:8
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Jun 03, 2020 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Apr 04, 2013 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Nov 01, 2021 | NM_000050.4(ASS1):c.1087C>T(R363W) is a missense variant classified as likely pathogenic in the context of citrullinemia type 1. R363W has been observed in cases with relevant disease (PMID: 16124451, 26117549, 2358466, 14680976, 25537548, 31056765, 30904546). Functional assessments of this variant are available in the literature (PMID: 31469252). Internal structural analysis of the variant is supportive of pathogenicity. R363W has been observed in population frequency databases (gnomAD: AFR 0.01%). In summary, NM_000050.4(ASS1):c.1087C>T(R363W) is a missense variant that has both functional and internal structural support for pathogenicity and has been observed more frequently in cases with the relevant disease than in healthy populations. Please note: this variant was assessed in the context of healthy population screening. - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 20, 2024 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Sep 26, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Oct 04, 2019 | The ASS1 c.1087C>T, p.Arg363Trp variant (rs121908640) is reported in the literature in multiple individuals affected with citrullinemia, either in a homozygous state or compound heterozygous with another pathogenic variant (Diez-Fernandez 2017, Faghfoury 2011, Gao 2003, Haberle 2003, Kobayashi 1990, Mohamed 2015, Wasant 2005). This variant is reported as pathogenic or likely pathogenic by multiple laboratories in ClinVar (Variation ID: 6328), and is only observed on 8 alleles in the Genome Aggregation Database, indicating it is not a common polymorphism. The arginine at codon 363 is moderately conserved, and computational analyses (SIFT: damaging, PolyPhen-2: benign) predict conflicting effects of this variant on protein structure/function. However, arginine 363 is implicated in tetramer binding, which is critical for protein function (Diez-Fernandez 2017). Additionally, other amino acid substitutions at this codon (Gly, Leu, Gln) have been reported in individuals with citrullinemia (Gao 2003, Mohamed 2015). Based on available information, the p.Arg363Trp variant is considered to be pathogenic. References: Diez-Fernandez C et al. Mutations in the Human Argininosuccinate Synthetase (ASS1) Gene, Impact on Patients, Common Changes, and Structural Considerations. Hum Mutat. 2017 May;38(5):471-484. Faghfoury H et al. Transient fulminant liver failure as an initial presentation in citrullinemia type I. Mol Genet Metab. 2011; 102(4):413-7. Gao H et al. Identification of 16 novel mutations in the argininosuccinate synthetase gene and genotype-phenotype correlation in 38 classical citrullinemia patients. Hum Mutat. 2003; 22(1):24-34. Haberle J et al. Mild citrullinemia in Caucasians is an allelic variant of argininosuccinate synthetase deficiency (citrullinemia type 1). Mol Genet Metab. 2003 Nov;80(3):302-6. Kobayashi K et al. Heterogeneity of mutations in argininosuccinate synthetase causing human citrullinemia. J Biol Chem. 1990; 265(19):11361-7. Mohamed S et al. Neurometabolic Disorders-Related Early Childhood Epilepsy: A Single-Center Experience in Saudi Arabia. Pediatr Neonatol. 2015 Dec;56(6):393-401. Wasant P et al. Argininosuccinate synthetase deficiency: mutation analysis in 3 Thai patients. Southeast Asian J Trop Med Public Health. 2005; 36(3):757-61. - |
Pathogenic, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center | Sep 22, 2024 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 31, 2018 | - - |
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Center for Pediatric Genomic Medicine, Children's Mercy Hospital and Clinics | Jun 30, 2015 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jan 10, 2025 | Published functional studies demonstrate reduced enzyme activity (PMID: 31469252); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 31208364, 14680976, 21227727, 26117549, 16124451, 28750687, 28111830, 28132756, 2358466, 25537548, 8792870, 32778825, 12815590, 31469252, 37485339, 37308883, 6819208, 35095998, 35726796) - |
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Apr 25, 2018 | - - |
Citrullinemia Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Dec 30, 2021 | Variant summary: ASS1 c.1087C>T (p.Arg363Trp) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 3.2e-05 in 250206 control chromosomes (gnomAD). c.1087C>T has been reported in the literature in multiple homozygous and compound heterozygous individuals affected with Citrullinemia Type I (e.g. Haberle_2003, Wasant_2005, Zielonka_2019). These data indicate that the variant is very likely to be associated with disease. At least one publication reported experimental evidence evaluating an impact on protein function, and demonstrated severely diminished activity compared to the wild type (Zielonka_2019). Six clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014, and all laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 25, 2024 | This sequence change replaces arginine, which is basic and polar, with tryptophan, which is neutral and slightly polar, at codon 363 of the ASS1 protein (p.Arg363Trp). This variant is present in population databases (rs121908640, gnomAD 0.007%). This missense change has been observed in individual(s) with citrullinemia type 1 (PMID: 2358466, 12815590, 14680976, 16124451, 25537548, 26117549, 28111830). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 6328). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ASS1 protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects ASS1 function (PMID: 8792870). For these reasons, this variant has been classified as Pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at